Overview

* CalciMedica ( CALC ) reports Q3 net loss of $7.8 mln vs $5.6 mln year-ago

* Positive FDA discussions on pivotal trial for acute pancreatitis, design expected 1H 2026

Outlook

* Company expects cash position to fund operations into 2H 2026

* CalciMedica ( CALC ) expects pivotal trial design for AP finalized in 1H 2026

* Data from Phase 2 KOURAGE trial expected in 1H 2026

Result Drivers

* COSTS - R&D costs rose to $3.9 mln from $3.6 mln, while G&A expenses dropped to $1.8 mln from $2.2 mln

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$7.80

Income mln

Q3 Basic -$0.52

EPS

Q3 -$5.62

Income mln

From

Operatio

ns

Q3 $5.62

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for CalciMedica Inc ( CALC ) is $15.50, about 79.3% above its November 11 closing price of $3.21

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)